Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?

J Am Coll Cardiol. 2022 Oct 4;80(14):1299-1301. doi: 10.1016/j.jacc.2022.08.722.

¹ Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: ana.devesa@externo.cnic.es.
² Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Cardiology Department, IIS Fundación Jiménez Díaz University Hospital, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, Spain.
³ Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA.

No abstract available

Keywords: aspirin; cardiovascular disease; genetics; lipoprotein(a); primary prevention.

Publication types